Jefferies flags Spravato demand momentum at Johnson & Johnson as potential read-through for psychedelic drug peers

Johnson & Johnson’s Spravato business is drawing attention from Wall Street as a possible read-through for the psychedelic drug development space, according to a recent report referenced by Proactive Investors. Jefferies argued that growth in Spravato sales supports the case for a broader market opportunity for psychedelic-assisted therapies aimed at treatment-resistant depression.

Spravato is Johnson & Johnson’s brand for esketamine, delivered as a nasal spray and used alongside an oral antidepressant for specific depression populations, including people with treatment-resistant depression. Because Spravato is already sold commercially, it offers a rare “real world” datapoint for how clinicians and payers adopt a psychedelic-derived medicine after it clears regulatory hurdles.

The Jefferies view, as summarized in the Proactive Investors article, suggests that if Spravato continues to show momentum, investors may reassess the timeline and potential size of opportunity for companies building psychedelic programs. The report cites psychedelic developers including Atai Life Sciences, Compass Pathways and Cybin as potential beneficiaries of a sentiment shift tied to Spravato’s performance.

In the report’s framing, mainstream uptake matters to early-stage and late-stage developers because it can influence expectations about clinical differentiation, reimbursement and the willingness of healthcare systems to fund similar therapies. Even without direct commercial overlap, patient and prescriber familiarity can lower perceived adoption barriers for next-generation products, particularly those targeting similar diagnostic labels and using comparable assisted-therapy models.

Atai Life Sciences, which has been a prominent psychedelic investment vehicle, is among the companies listed. Compass Pathways is another, focused on developing psilocybin-based therapies for depression. Cybin is also included, with a platform built around psychedelic compounds intended for therapeutic use. The common thread is that these developers are still working to prove market scale, commercial pathways and longer-term evidence beyond initial trial results.

For Johnson & Johnson, Spravato’s role is less about creating a new category from scratch and more about sustaining adoption of an already approved therapy within a tightly regulated care pathway. Growth in a category leader can also shape how analysts build probability-weighted forecasts for the wider pipeline, since it provides a tangible benchmark for conversion from approvals to prescribing and reimbursement.

That said, the Proactive Investors summary does not provide specific sales figures, growth rates, or detailed assumptions from Jefferies in the portion available for this editorial review. It also does not spell out whether Jefferies expects a direct demand “spillover” from Spravato into competitor products, or whether it is mainly pointing to a broader investor sentiment and valuation read-through tied to the category’s commercial viability.

What to watch next for investors and the sector is whether Johnson & Johnson’s Spravato trajectory continues to strengthen and whether additional evidence emerges on payer coverage, prescribing breadth and treatment outcomes in routine practice. For psychedelic developers, the key question is whether any improved sentiment translates into concrete milestones such as clinical data catalysts, regulatory progress, partnership momentum and, eventually, the ability to secure reimbursement at scale.